<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859404</url>
  </required_header>
  <id_info>
    <org_study_id>GRC 3886-201</org_study_id>
    <nct_id>NCT00859404</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma</brief_title>
  <official_title>A 12-week Randomized, Double-blind, Parallel Group, Placebo-controlled Dose Range Finding Study to Evaluate the Efficacy of Oglemilast in the Treatment of Stable Mild to Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals Europe Ltd. (R&amp;D)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Pharmaceuticals Europe Ltd. (R&amp;D)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed at evaluating efficacy and safety of oglemilast in the treatment of stable
      mild to moderate persistent asthma. The study involves two weeks of run in period. This is a
      placebo controlled study. One of the four treatment arms is placebo. The duration of
      treatment is 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morning pre-dose FEV1 at day 85 compared with pre-dose FEV1 value at day 1</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at days 8, 36 and 64 in morning pre-dose FEV1</measure>
    <time_frame>Days 8, 36, 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at days 8, 36 and 64 in morning pre-dose vital capacity (FVC), peak expiratory flow (PEF), forced expiratory flow 25-75% (FEF25-75%)</measure>
    <time_frame>days 8, 36 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in morning and evening PEF (based on patient diary)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in asthma day time symptom score from baseline at day 85</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in asthma night time symptom score from baseline at day 85</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of night time awakenings from baseline at day 85</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and the use of rescue (reliever) medication (salbutamol)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of asthma exacerbations</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator global impression of change from baseline to day 85</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of change from baseline to day 85</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of oglemilast</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1. oglemilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. oglemilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3. oglemilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4. placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oglemilast</intervention_name>
    <description>Tablet oglemilast or placebo once a day, for 12 weeks</description>
    <arm_group_label>1. oglemilast</arm_group_label>
    <arm_group_label>2. oglemilast</arm_group_label>
    <arm_group_label>3. oglemilast</arm_group_label>
    <arm_group_label>4. placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          -  Adult patients with a physician-documented diagnosis of chronic, stable, persistent,
             mild to moderate asthma (clinical symptoms and documented reversibility of airway
             obstruction, with an FEV1 of 60% to 85% of the predicted value).

        The following criteria must be met at the randomisation visit:

          -  At least 80% compliance during the single-blind placebo run-in period

          -  FEV1 between 60% and 85% of the predicted value

          -  Without asthma exacerbation during the run-in period

          -  Reversibility: patients are required to demonstrate a ≥ 12% increase in FEV1 (with an
             absolute improvement in FEV1 of at least 200mL) ≥ 10 min and up to 15 minutes after
             inhalation of 400 μg salbutamol via a spacer

          -  Any symptom score being ≥ 1 for at least 4 out of the last 7 days of the run-in

          -  Use of salbutamol for symptom relief on &gt; 2 occasions on at least 4 out of the last 7
             days of the run-in
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Glenmark investigational sites (28)</name>
      <address>
        <city>Mumbai, Bangalore etc</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>September 23, 2009</last_update_submitted>
  <last_update_submitted_qc>September 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Narendra Maharaj</name_title>
    <organization>Glenmark Pharmaceuticals Ltd</organization>
  </responsible_party>
  <keyword>Mild to moderate persistent asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

